Literature DB >> 19245432

Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database.

W Marieke Schoonen1, Gena Kucera, Jenna Coalson, Lin Li, Mark Rutstein, Fionna Mowat, Jon Fryzek, James A Kaye.   

Abstract

The epidemiology of immune thrombocytopenic purpura (ITP) is not well-characterised in the general population. This study described the incidence and survival of ITP using the UK population-based General Practice Research Database (GPRD). ITP patients first diagnosed in 1990-2005 were identified in the GPRD. Overall incidence rates (per 100,000 person-years) and rates by age, sex, and calendar periods were calculated. Survival analysis was conducted using the Kaplan-Meier and proportional hazard methods. A total of 1145 incident ITP patients were identified. The crude incidence was 3.9 (95% confidence interval [CI]: 3.7-4.1). Overall average incidence was statistically significantly higher in women (4.4, 95% CI: 4.1-4.7) compared to men (3.4; 95% CI: 3.1-3.7). Among men, incidence was bimodal with peaks among ages under 18 and between 75-84 years. The hazard ratio for death among ITP patients was 1.6 (95% CI: 1.3-1.9) compared to age- and sex-matched comparisons. During follow-up 139 cases died, of whom 75 had a computerised plausible cause of death. Death was related to bleeding in 13% and infection in 19% of these 75. In conclusion, ITP incidence varies with age and is higher in women than men. This potentially serious medical condition is associated with increased mortality in the UK.

Entities:  

Mesh:

Year:  2009        PMID: 19245432     DOI: 10.1111/j.1365-2141.2009.07615.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  55 in total

Review 1.  Romiplostim: a review of its use in immune thrombocytopenia.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

2.  Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan.

Authors:  Takaaki Hato; Naoki Shimada; Yoshiyuki Kurata; Masataka Kuwana; Kingo Fujimura; Hirokazu Kashiwagi; Toshiro Takafuta; Mitsuru Murata; Yoshiaki Tomiyama
Journal:  Blood Adv       Date:  2020-04-28

Review 3.  Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.

Authors:  Bing-Bing Yang; Sameer Doshi; Karen Arkam; Janet Franklin; Andrew T Chow
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 4.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

5.  [Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].

Authors:  Ingrid Pabinger; Günther Gastl; Michael Steurer; Siegfried Sormann; Michael Fillitz; Josef Friedl; Dietmar Geissler; Klaus Geissler; Richard Greil; Paul Knöbl; Sibylle Kozek-Langenecker; Peter Krippl; Paul Kyrle; Alois Lang; Werner Linkesch; Heinz Ludwig; Markus Müller; Simon Panzer; Elisabeth Pittermann; Josef Thaler; Ansgar Weltermann
Journal:  Wien Klin Wochenschr       Date:  2012-03-03       Impact factor: 1.704

6.  Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome.

Authors:  Lamiae Grimaldi-Bensouda; Clémentine Nordon; Marc Michel; Jean-François Viallard; Daniel Adoue; Nadine Magy-Bertrand; Jean-Marc Durand; Philippe Quittet; Olivier Fain; Bernard Bonnotte; Anne-Sophie Morin; Nathalie Morel; Nathalie Costedoat-Chalumeau; Brigitte Pan-Petesch; Mehdi Khellaf; Antoinette Perlat; Karim Sacre; François Lefrere; Lucien Abenhaim; Bertrand Godeau
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

Review 7.  Immune thrombocytopenia and pregnancy.

Authors:  Srividhya Sankaran; Susan E Robinson
Journal:  Obstet Med       Date:  2011-10-25

8.  Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle.

Authors:  Andreas Rank; Oliver Weigert; Helmut Ostermann
Journal:  Biologics       Date:  2010-05-25

9.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines.

Authors:  Steven Black; Juhani Eskola; Claire-Anne Siegrist; Neal Halsey; Noni MacDonald; Barbara Law; Elizabeth Miller; Nick Andrews; Julia Stowe; Daniel Salmon; Kirsten Vannice; Hector S Izurieta; Aysha Akhtar; Mike Gold; Gabriel Oselka; Patrick Zuber; Dina Pfeifer; Claudia Vellozzi
Journal:  Lancet       Date:  2009-10-31       Impact factor: 79.321

10.  Seasonal Association of Immune Thrombocytopenia in Adults.

Authors:  Anıl Tombak; Burcu Boztepe; Naci Tiftik; Melda Cömert; Ozan Salim; Kaniye Aydın; Emel Gürkan; Orhan Kemal Yücel; Güray Saydam; Mehmet Ali Sungur
Journal:  Balkan Med J       Date:  2015-10-01       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.